Literature DB >> 26376958

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.

Annette E Hay1, Alli Murugesan2, Ashley M DiPasquale3, Tom Kouroukis4, Irwindeep Sandhu5, Vishal Kukreti6, Nizar J Bahlis7, Johan Lategan7, Donna E Reece6, John F Lyons8, Joana Sederias1, Hao Xu1, Jean Powers1, Lesley K Seymour1, Tony Reiman2,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26376958     DOI： 10.3109/10428194.2015.1091927

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  12 in total

Review 1.  Aurora B kinase: a potential drug target for cancer therapy.

Authors:  Azaj Ahmed; Anas Shamsi; Taj Mohammad; Gulam Mustafa Hasan; Asimul Islam; Md Imtaiyaz Hassan
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-28       Impact factor: 4.553

Review 2.  Multi-kinase inhibitors, AURKs and cancer.

Authors:  Jonas Cicenas; Erikas Cicenas
Journal:  Med Oncol       Date:  2016-04-01       Impact factor: 3.064

Review 3.  The therapeutic potential of cell cycle targeting in multiple myeloma.

Authors:  Anke Maes; Eline Menu; Kim De Veirman; Ken Maes; Karin Vand Erkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2017-06-28

4.  Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.

Authors:  Cornelis J Korbee; Matthias T Heemskerk; Dragi Kocev; Elisabeth van Strijen; Omid Rabiee; Kees L M C Franken; Louis Wilson; Nigel D L Savage; Sašo Džeroski; Mariëlle C Haks; Tom H M Ottenhoff
Journal:  Nat Commun       Date:  2018-01-24       Impact factor: 14.919

5.  FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.

Authors:  N Yang; C Wang; Z Wang; S Zona; S-X Lin; X Wang; M Yan; F-M Zheng; S-S Li; B Xu; L Bella; J-S Yong; E W-F Lam; Q Liu
Journal:  Oncogene       Date:  2017-01-23       Impact factor: 9.867

6.  Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.

Authors:  Laura Mazzera; Manuela Abeltino; Guerino Lombardi; Anna Maria Cantoni; Roberto Ria; Micaela Ricca; Ilaria Saltarella; Valeria Naponelli; Federica Maria Angela Rizzi; Roberto Perris; Attilio Corradi; Angelo Vacca; Antonio Bonati; Paolo Lunghi
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

Review 7.  Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.

Authors:  Ruijuan Du; Chuntian Huang; Kangdong Liu; Xiang Li; Zigang Dong
Journal:  Mol Cancer       Date:  2021-01-15       Impact factor: 27.401

Review 8.  "Do We Know Jack" About JAK? A Closer Look at JAK/STAT Signaling Pathway.

Authors:  Emira Bousoik; Hamidreza Montazeri Aliabadi
Journal:  Front Oncol       Date:  2018-07-31       Impact factor: 6.244

9.  Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach.

Authors:  Wenxiang Bai; Honghua Wang; Hua Bai
Journal:  Pharmgenomics Pers Med       Date:  2019-12-31

10.  High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro.

Authors:  Laura Torrente; Gunjit Maan; Asma Oumkaltoum Rezig; Jean Quinn; Angus Jackson; Andrea Grilli; Laura Casares; Ying Zhang; Evgeny Kulesskiy; Jani Saarela; Silvio Bicciato; Joanne Edwards; Albena T Dinkova-Kostova; Laureano de la Vega
Journal:  Biomolecules       Date:  2020-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.